Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders
- PMID: 30365357
- DOI: 10.1146/annurev-med-081117-041238
Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders
Abstract
Fragile X syndrome (FXS) is the most frequent inherited form of intellectual disability and autism spectrum disorder. Loss of the fragile X mental retardation protein, FMRP, engenders molecular, behavioral, and cognitive deficits in FXS patients. Experiments using different animal models advanced our knowledge of the pathophysiology of FXS and led to the discovery of many targets for drug treatments. In this review, we discuss the potential of metformin, an antidiabetic drug approved by the US Food and Drug Administration, to correct core symptoms of FXS and other neurological disorders in humans. We summarize its mechanisms of action in different animal and cellular models and human diseases.
Keywords: ERK; autism spectrum disorders; fragile X syndrome; mTOR; metformin; protein synthesis.
Similar articles
-
Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.Adv Exp Med Biol. 2012;970:517-51. doi: 10.1007/978-3-7091-0932-8_23. Adv Exp Med Biol. 2012. PMID: 22351071 Review.
-
Translational endpoints in fragile X syndrome.Neurosci Biobehav Rev. 2014 Oct;46 Pt 2:256-69. doi: 10.1016/j.neubiorev.2013.10.012. Epub 2013 Oct 30. Neurosci Biobehav Rev. 2014. PMID: 24184744 Review.
-
Toward fulfilling the promise of molecular medicine in fragile X syndrome.Annu Rev Med. 2011;62:411-29. doi: 10.1146/annurev-med-061109-134644. Annu Rev Med. 2011. PMID: 21090964 Free PMC article. Review.
-
Metformin ameliorates core deficits in a mouse model of fragile X syndrome.Nat Med. 2017 Jun;23(6):674-677. doi: 10.1038/nm.4335. Epub 2017 May 15. Nat Med. 2017. PMID: 28504725
-
R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.Int J Neuropsychopharmacol. 2015 Mar 28;18(9):pyv034. doi: 10.1093/ijnp/pyv034. Int J Neuropsychopharmacol. 2015. PMID: 25820841 Free PMC article.
Cited by
-
Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders.Pharmaceuticals (Basel). 2023 Dec 11;16(12):1714. doi: 10.3390/ph16121714. Pharmaceuticals (Basel). 2023. PMID: 38139841 Free PMC article. Review.
-
Neurodevelopment and early pharmacological interventions in Fragile X Syndrome.Front Neurosci. 2023 Aug 2;17:1213410. doi: 10.3389/fnins.2023.1213410. eCollection 2023. Front Neurosci. 2023. PMID: 37599992 Free PMC article. Review.
-
Progranulin is an FMRP target that influences macroorchidism but not behaviour in a mouse model of Fragile X Syndrome.Curr Res Neurobiol. 2023 Jun 16;5:100094. doi: 10.1016/j.crneur.2023.100094. eCollection 2023. Curr Res Neurobiol. 2023. PMID: 37416094 Free PMC article.
-
Why Don't the Mutant Cells That Evade DNA Repair Cause Cancer More Frequently? Importance of the Innate Immune System in the Tumor Microenvironment.Int J Mol Sci. 2023 Mar 6;24(5):5026. doi: 10.3390/ijms24055026. Int J Mol Sci. 2023. PMID: 36902456 Free PMC article. Review.
-
Drosophila melanogaster as a Model to Study Fragile X-Associated Disorders.Genes (Basel). 2022 Dec 28;14(1):87. doi: 10.3390/genes14010087. Genes (Basel). 2022. PMID: 36672829 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
